Novavax (NVAX) : Simplex Trading added new position in Novavax during the most recent quarter end. The investment management firm now holds 214,668 shares of Novavax which is valued at $386,402 , the company said in a statement filed on Oct 7, 2016 with the SEC.Novavax makes up approximately 0.05% of Simplex Trading’s portfolio.
Other Hedge Funds, Including , Bnp Paribas Arbitrage Sa reduced its stake in NVAX by selling 17,205 shares or 14.92% in the most recent quarter. The Hedge Fund company now holds 98,074 shares of NVAX which is valued at $197,129.
Novavax closed down -0.08 points or -4.26% at $1.8 with 2,07,52,399 shares getting traded on Friday. Post opening the session at $1.72, the shares hit an intraday low of $1.61 and an intraday high of $1.85 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Novavax reported $-0.29 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on Aug 9, 2016. Analyst had a consensus of $-0.25. The company had revenue of $2.50 million for the quarter, compared to analysts expectations of $8.10 million. The company’s revenue was down -82.1 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.08 EPS.
Many Wall Street Analysts have commented on Novavax. Shares were Reiterated by Chardan Capital Markets on Sep 20, 2016 to “Neutral” and Lowered the Price Target to $ 1.50 from a previous price target of $5.75 .Novavax was Downgraded by Citigroup to ” Neutral” on Sep 16, 2016. Shares were Downgraded by Wedbush on Sep 16, 2016 to ” Neutral” and Lowered the Price Target to $ 2 from a previous price target of $14 .
Novavax Inc. (Novavax) is a clinical-stage vaccine company engaged in the discovery development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. The Company’s product pipeline focuses on a variety of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV) seasonal influenza pandemic influenza and the Ebola virus (EBOV). The Company’s lead adjuvant for human applications Matrix-M is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. The Company is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. The Company is developing additional pre-clinical stage programs in a variety of infectious diseases including Middle East respiratory syndrome (MERS).